Two funds walk into a table. Only the numbers talk.
Tata India Pharma & Healthcare Fund vs Nippon India Taiwan Equity Fund
Pick two or three funds. We’ll tell you in plain words which grew faster, which was calmer, which costs less and what your money would have become. Figures are for the Direct plan, Growth option, where a fund has one.
- ATata India Pharma & Healthcare Fund
Tata Mutual Fund- Sectoral / Thematic Fund
- Direct plan
- Very High Risk
NAV ₹39.76 on 13 Nov 2026
- BNippon India Taiwan Equity Fund
Nippon India Mutual Fund- Sectoral / Thematic Fund
- Direct plan
- Very High Risk
NAV ₹28.76 on 13 Nov 2026
The short version
Who comes out ahead on each measure, over the 3 years all of them have been around.
Grew faster
BNippon India Taiwan Equity Fund
Nippon India Taiwan Equity Fund returned 46.5% a year over 3 years, against 19% for Tata India Pharma & Healthcare Fund. ₹1 lakh invested 3 years ago would be about ₹3.15 Lakh today, against ₹1.68 Lakh.
Smoother ride
ATata India Pharma & Healthcare Fund
Tata India Pharma & Healthcare Fund swung the least: about 13.4% a year either way, against 38.1% for Nippon India Taiwan Equity Fund. Lower means fewer scary days.
Fell less in a crash
No fair winner yet
At its worst, Tata India Pharma & Healthcare Fund fell 18.5% from its peak, against 44.8% for Nippon India Taiwan Equity Fund. On ₹1 lakh, that's a dip to ₹55,225 at the bottom for Nippon India Taiwan Equity Fund. Could you have held on?
Not a fair fight: we only have data for Nippon India Taiwan Equity Fund (from Dec 2021), so it has not been through the 2020 crash the others fell in.
More consistent
No fair winner yet
Pick any day in the past and hold for a year: Nippon India Taiwan Equity Fund ended up in profit 86% of the time, against 76% for Tata India Pharma & Healthcare Fund.
Not a fair fight: we only have data for Nippon India Taiwan Equity Fund (from Dec 2021), so it has not been through the 2020 crash the others fell in.
What your money would have become
The same amount, put into each fund on the same day.
The dashed line is the ₹10,000 you put in. Above it is profit, below it is loss.
- ATata India Pharma & Healthcare Fund₹16,565 from ₹10,000(18.4% a year)
- BNippon India Taiwan Equity Fund₹30,587 from ₹10,000(45.3% a year)
A one-time ₹10,000 put in 3 years ago, valued at the latest NAV. This is what happened, not what will.
Strengths and watch-outs
Each fund judged against its own category, and against a 5-year SBI FD at 6.05%.
ATata India Pharma & Healthcare Fund
- Strength: Ahead of its category: 15.8% a year over 5 years, against a category average of 12.5%
- Strength: In the top quarter of its category over 5 years (#25 of 100)
- Strength: Beat a 5-year SBI FD: 15.8% a year over 5 years, against 6.05%
- Strength: Swings less than most funds in its category
- Strength: Fell less than its category in the worst crash
BNippon India Taiwan Equity Fund
- Strength: Ahead of its category: 46.5% a year over 3 years, against a category average of 15%
- Strength: In the top quarter of its category over 3 years (#1 of 139)
- Strength: Beat a 5-year SBI FD: 46.5% a year over 3 years, against 6.05%
- Watch out: Swings more than most funds in its category
All the numbers
The stronger figure in each row is marked Best. Under each return is the fund’s rank in its category and the category average.
| Measure | ATata India Pharma & Healthcare Fund | BNippon India Taiwan Equity Fund |
|---|---|---|
| ReturnsHow much the fund grew. Beyond a year, this is per year (annualised). | ||
| 1 yearLast 12 months, the most noisy figure | 10.4%#59 of 226 · avg 6.1% | 60.6%Best#1 of 226 · avg 6.1% |
| 3 yearsPer year, over a full market mood swing | 19%#33 of 139 · avg 15% | 46.5%Best#1 of 139 · avg 15% |
| 5 yearsPer year, the fairest single test | 15.8%#25 of 100 · avg 12.5% | – |
| 10 yearsPer year, across bull and bear markets | 15.7%#33 of 68 · avg 15% | – |
| RiskHow bumpy the ride was. This is what decides whether you stay invested. | ||
| Ups and downsVolatility: how far it swings in a typical year. Lower is calmer | 13.4%Bestcategory avg 15.8% | 38.1%category avg 15.8% |
| Worst fallThe biggest drop from a peak in 10 years. Lower is better | −18.5%category avg −25.5% | −44.8%data from 14 Dec 2021 only |
| Best 12 monthsIts strongest year | 76.3% | 279.5%data from 14 Dec 2021 only |
| Worst 12 monthsIts weakest year | -17.3% | -33.6%data from 14 Dec 2021 only |
| Odds of a gainShare of all 1-year holding periods that ended in profit | 76% | 86%data from 14 Dec 2021 only |
| Cost and sizeThe fee comes out of your returns every year, whether the fund does well or not. | ||
| Expense ratioYearly fee. Lower keeps more for you | 1.07% | 1.06%Best |
| Fund sizeMoney managed (AUM). Neither better nor worse | ₹1,511 Cr | ₹1,147 Cr |
| Minimum SIPSmallest monthly amount | ₹100 | – |
| Lock-inTime before you can withdraw | None | None |
“Best” is not a recommendation: a fund that returned more usually took more risk to do it.
Which one fits you?
There is no best fund, only a better fit for what you need the money to do.
ATata India Pharma & Healthcare Fund
Might suit you if…
- a smoother ride matters more to you than the top return
BNippon India Taiwan Equity Fund
Might suit you if…
- you want the stronger long-run growth and can sit through sharper falls